Search

• Novel 1,2,3-triazole linked coumarin hybrids were synthesized. • Antidiabetic efficacy of synthesized hybrids studied against α-amylase. • Computational investigations were carried out on synthesized hybrids. Novel 1,2,3-triazole linked coumarin and cinnamic acid analogs were designed, synthesized, characterized, and evaluated for their ability to inhibit the α-amylase enzyme in order to treat diabetes. Porcine pancreatic α-amylase isoenzyme II was used in the investigation and analysis of in silico molecular docking and molecular dynamic simulations. The server PreADME/toxicity was used to predict pharmacokinetics and pharmacodynamics properties. In vitro and in silico results revealed that compounds 7d, 7e and 7f showed excellent antidiabetic activity with IC 50 in the range of 0.133–0.192 μM and percentage inhibitions in the range of 88.22±1.43 to 98.87±2.63%, respectively, indicating their better potency than the standard acarbose. Furthermore, synthesized compounds were docked into the active sites of the porcine pancreatic alpha-amylase isoenzyme II to evaluate binding affinity and hybrid most potent 7f was lodged in the active site via many strong hydrogen and hydrophobic interactions. Through a 100-ns dynamic simulation research, stability and binding interactions between the promising hybrid 7f and the active residues of the investigated α-amylase isoenzyme II were confirmed. The biological assessments, ADMET, molecular docking, and MD simulations of synthesized analogs allude to the possibility of using hybrids 7d, 7e, and 7f in the development of new antidiabetic therapeutics. [Display omitted] [ABSTRACT FROM AUTHOR]

• The leishmanicidal activity of a triazole-phthalimide derivative (PT4) was evaluated. • PT4 decrease the growth and survival of promastigote and amastigotes. • PT4 showed inhibitory potential over the CYP51 enzyme of Leishmania spp. • PT4 induced an increase in ROS and depolarization of the mitochondrial membrane. • Our results pointed PT4 as a promissory agent against Cutaneous Leishmaniasis. Organic compounds obtained by click chemistry reactions have demonstrated a broad spectrum of biological activities being widely applied for the development of molecules against pathogens of medical and veterinary importance. Cutaneous leishmaniasis (CL), caused by intracellular protozoa parasite of genus Leishmania , comprises a complex of clinical manifestations that affect the skin and mucous membranes. The available drugs for the treatment are toxic and costly, with long periods of treatment, and the emergence of resistant strains has been reported. In this study we investigated the in vitro effects of a phthalimide-1,2,3-triazole derivative, the 4-Phenyl-1-[2-(phthalimido-2-yl)ethyl]-1H-1,2,3-triazole (PT4) obtained by click chemistry , on mammalian cells and on L. amazonensis and L. braziliensis , the causative agents of CL in Brazil. In silico ADMET evaluation of PT4 showed that this molecule has good pharmacokinetic properties with no violation of Lipinski's rules. The in vitro assays showed that PT4 was more selective for both Leishmania species than to mammalian cells. This compound also presented low cytotoxicity to mammalian cells with CC 50 > 500 μM. Treatment of promastigote forms with different concentrations of PT4 resulted in ultrastructural alterations, such as plasma membrane wrinkling, shortening of cell body, increased cell volume and cell rupture. The molecular dynamic simulations showed that PT4 interacts with Lanosterol 14 α-demethylase from Leishmania, an essential enzyme of lipid synthesis pathway in this parasite. Our results demonstrated PT4 was effective against both species of Leishmania. PT4 caused a decrease of mitochondrial membrane potential and increased production of reactive oxygen species, which may lead to parasite death. Taken together, our results pointed PT4 as promissing therapeutic agent against CL. [ABSTRACT FROM AUTHOR]